Edge Health analysis and insight on the COVID-19 pandemic
Protecting the NHS 

Authors

Context 

In early 2020, Edge Health undertook and published the first major UK (and European) study on the potential impact of the COVID-19 pandemic on the NHS. This study, which received extensive coverage in national and international newspapers, TV and radio, helped to build the early evidence base for COVID-19.

Ultimately, many commentators commended Edge Health's work for its contribution to helping save the NHS from the near catastrophe that it faced in Spring 2020. 

Our support

Edge Health's support to the NHS has been threefold: 

  • Regular (often daily) thought leadership, which was shared widely through our newsletter, mailing, and social media presence during the COVID-19 crisis of early 2020. Often this thought leadership made it into mainstream national and local press. 

  • Urgent support to NHS hospitals and health systems during the early stage of the pandemic, which ranged from predicting demand for beds (more here), predicting demand more generally for workforce, PPE, and community workforce, through to ensuring hospitals retained critical care capacity for treating cancer patients (more here). 

  • On-going support to the NHS with its recovery, including work for the Getting It Right First Time program to track High-Volume Low-Complexity procedures across organisations to help drive the recovery and delivery of activity. 

History of our support

In late 2020, landmark work from Edge Health and Oxera led to the removal of the UK's blanket 14 day quarantine restrictions for international travelers.

 

This quarantine restriction was replaced by a greater reliance on COVID testing - a trend seen across the globe in 2021. The policy towards testing evolved over 2021 with support from Edge Health and Oxera, which in general sought to clarify the diminishing value of multiple tests. 

It was not until early 2022 that the true extent of the limited value of international travel restrictions became clear in the aftermath of the Omicron wave of infections - a wave of infections totally unaffected by the extensive international travel restrictions in place at the point in time. 

Since early 2022, Edge Health and Oxera have provided similar insight and support across Europe, and most recently for Japan in Asia. 

Further details of our work

 

Further information ​on our work can be found below. For additional information, please contact George (george@edgehealth.co.uk) or Jennifer (jennifer@edgehealth.co.uk). 

Edge_George_small.jpg